Category: Industry

October 13, 2021

Spark Therapeutics has secured the exclusive rights to CombiGene’s CG01 therapy, which aims to treat drug resistant focal epilepsy, in a deal worth $8.5m in advance with further payments due on reaching clinical milestones. The news sent Swedish firm CombiGene’s […]

October 13, 2021

Millions of people who received the Pfizer COVID-19 vaccine have been eligible to get a third booster dose for weeks, but those who received the other FDA-authorized shots have been waiting to see whether they’ll need another dose. They’ll soon […]

October 13, 2021

Scientists at the FDA and Centers for Disease Control and Prevention have been grappling with the question of who needs an additional vaccine dose, and when, for weeks now. The authorization of a third dose of Pfizer and BioNTech’s vaccine […]

October 12, 2021

With more than a touch of inevitability, CureVac is abandoning its first mRNA COVID vaccine after dismal results earlier this year and switching focus to a second mRNA asset with GlaxoSmithKline. A lot was expected from the little German biotech […]

October 12, 2021

In October, Chetan Goudar, PhD, vice president at Amgen process development, and his colleagues wrote in Current Opinion in Biotechnology: “Rapid technological advances have significantly improved the capability, versatility, and robustness of mass spectrometers which has led to them playing […]

October 11, 2021

Although the UK recognises those who are in COVID-19 vaccine trials as fully vaccinated for the purpose of certification, most other countries do not currently recognise clinical trial volunteers who have not had a vaccine that is approved for deployment. […]

October 8, 2021

Researchers show combining mass spectrometry and a gas-phase electrophoretic mobility molecular analyser improves detection of full and empty virus-like particles for gene therapies. Adeno-associated viruses (AAV) are the leading virus-like particle (VLP) vehicles for gene therapies, but how can AAVs […]

October 6, 2021

Pfizer is paying Voyager $30 million upfront to get access to its TRACER adeno-associated virus (AAV) vector technology, which aims to improve the safety of gene therapies – a field that has suffered a string of safety scares in the […]

October 5, 2021

For the past several months, one of the many questions hanging over the booster debate has ben what do with people who got J&J’s shot. The company’s application, and the FDA’s planned meeting, creates a timeline for answering that question. […]

October 5, 2021

AstraZeneca has taken another step toward bringing its COVID-19 antibody cocktail to market, filing for emergency use authorization of the long-acting candidate in coronavirus prophylaxis in the U.S. Last month, AstraZeneca delivered evidence that the candidate prevents COVID-19 in people […]

October 4, 2021

Merck and partner Ridgeback Therapeutics have said they will see emergency use authorisation from the FDA for molnupiravir on the strength of the data, which suggest the drug could be used in the community to keep people from developing severe […]

October 4, 2021

Selecta Bioscience, a biotechnology company specializing in the development of tolerogenic therapies, announced an agreement to license its ImmTOR platform to Takeda on Oct. 4th, 2021. Takeda will use the platform to develop gene therapies for lysosomal storage disorders. For […]